Dynamic receptor-based pharmacophore model development and its application in designing novel HIV-1 integrase inhibitors

Journal of Medicinal Chemistry

Volumn 48, Issue 5, 2005, Pages 1496-1505

  Deng, Jinxia ^a,c   Lee, Keun Woo ^b,d   Sanchez, Tino ^c   Cui, Meng ^b   Neamati, Nouri ^c   Briggs, James M ^a,b  

^a University of Houston   (United States)

^b University of Houston   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d Gyeongsang National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; INTEGRASE; INTEGRASE INHIBITOR; MONOMER;

ARTICLE; DATA BASE; DRUG DESIGN; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; ENERGY; ENZYME ACTIVE SITE; ENZYME CONFORMATION; HUMAN IMMUNODEFICIENCY VIRUS 1; IC 50; MODEL; MOLECULAR DYNAMICS; NONHUMAN; PHARMACOPHORE; PROBABILITY; STRUCTURE ANALYSIS; VALIDATION PROCESS;

BINDING SITES; CATALYTIC DOMAIN; DRUG DESIGN; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MUTATION; PROBABILITY; PROTEIN CONFORMATION; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; THERMODYNAMICS;

EID: 14944359976     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm049410e     Document Type: Article

References (45)

1. Coffin, I. M.; Hughes, S. H.; Varmus, H. E. Retroviruses; Cold Spring Harbor Laboratory Press: New York, 1997.
2. Chen, I. J.; Neamati, N.; MacKerrell, A. D., Jr. Structure-based inhibitor design targeting HIV-1 integrase. Curr. Drug Targets Infect. Disord. 2002, 2, 217-234.
3. Neamati, N.; Sunder, S.; Pommier, Y. Design and Discovery of HIV-1 Integrase Inhibitors. DDT 1997, 2, 487-198.
4. Pommier, Y.; Marchand, C.; Neamati, N. Retroviral integrase inhibitors year 2000: update and perspectives. Antiviral Res. 2000, 47, 139-148.
5. Neamati, N. Structure-based HIV-1 integrase inhibitor design: a future perspective. Expert Opin. Investig. Drugs 2001, 10, 281-296.
6. Fesen, M. R.; Pommier, Y.; Leteurtre, F.; Hiroguchi, S.; Yung, J. et al. Inhibition of HIV-1 integrase by flavones, caffeic acid phenethyl ester (CAPE) and related compounds. Biochem. Pkarmacol. 1994, 48, 595-608.
7. Marchand, C.; Neamati, N.; Pommier, Y. In vitro human immunodeficiency virus type 1 integrase assays. Methods Enzymol. 2001, 340, 624-633.
8. Dayam, R.; Neamati, N. Small-molecule HIV-1 integrase inhibitors: the 2001-2002 update. Curr. Pharm. Des. 2003, 9, 1789-1802.
9. Singh, S. B.; Ondeyka, J. G.; Schleif, W. A.; Felock, P.; Hazuda, D. J. Chemistry and structure-activity relationship of HIV-1 integrase inhibitor integracide B and related natural products. J. Nat. Prod. 2003, 66, 1338-1344.
10. Hong, H.; Neamati, N.; Wang, S.; Nicklaus, M. C.; Mazumder, A. et al. Discovery of HIV-1 integrase inhibitors by pharmacophore searching. J. Med. Chem. 1997, 40, 930-936.
11. Nicklaus, M. C.; Neamati, N.; Hong, H.; Mazumder, A.; Sunder, S. et al. HIV-1 integrase pharmacophore: discovery of inhibitors through three-dimensional database searching. J. Med. Chem. 1997, 40, 920-929.
12. Hong, H.; Neamati, N.; Winslow, H. E.; Christensen, J. L.; Orr, A. et al. Identification of HIV-1 integrase inhibitors based on a four-point pharmacophore. Antiviral Chem. Chemother. 1998, 9, 461-472.
13. Carlson, H. A.; Masukawa, K. M.; Rubins, K; Bushman, F. D.; Jorgensen, W. L. et al. Developing a dynamic pharmacophore model for HIV-1 integrase. J. Med. Chem. 2000, 43, 2100-2114.
14. Young, S. L-780,810: a potent antiviral HIV integrase inhibitor with potential clinical utulity. Presented at The XIV International AIDS Conference, Barcelona, 2002.
15. Yoshinaga, T.; Sato, A.; Fujishita, T.; Fujiwara, T. Presented at 9th Conference on Retroviruses and Opportunistic Infections: Seattle, WA, 2002.
16. Goldgur, Y.; Craigie, R.; Cohen, G. H.; Fujiwara, T.; Yoshinaga, T. et al. Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: a platform for antiviral drug design. Proc. Natl. Acad. Sci. U. S. A. 1999, 96, 13040-13043.
17. Goldgur, Y.; Dyda, F.; Hickman, A. B.; Jenkins, T. M.; Craigie, R. et al. Three new structures of the core domain of HIV-1 integrase: an active site that binds magnesium. Proc. Natl. Acad. Sci. U. S. A. 1998, 95, 9150-9154.
18. Lins, R. D.; Briggs, J. M.; Straatsma, T. P.; Carlson, H. A.; Greenwald, J. et al. Molecular dynamics studies on the HIV-1 integrase catalytic domain. Biophys. J. 1999, 76, 2999-3011.
19. Wang, R.; Gao, Y.; Lai, L. LigBuilder: A multi-purpose program for structure-based drug design. J. Mol. Modelling 2000, 6, 498-516.
20. NWChem A Computational Chemistry Package for Parallel Computers, High Performance Computational Chemistry Group; 4.0 ed.; Pacific Northwest National Laboratory: Richland, WA 99352.
21. Catalyst; 4.6 ed.; Accelrys Inc: San Diego, CA.
22. O'Connor, S. D.; Smith, P. E.; al-Obeidi, F.; Pettitt, B. M. Quenched molecular dynamics simulations of tuftsin and proposed cyclic analogues. J. Med. Chem. 1992, 35, 2870-2881.
23. Shannon, R. D. Revised Effective Ionic Radii in Halides and Chalcogenides. Acta Crystallogr. 1976, A32, 751.
24. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and Computational Approaches to Estimate Solubility and Permeability in Drug Discovery and Development Settings. Adv. Drug Delivery Rev. 1997, 23, 3-25.
25. Schames, J. R.; Henchman, R. H.; Siegel, J. S.; Sotriffer, C. A.; Ni, H. et al. Discovery of a novel binding trench in HIV integrase. J. Med. Chem. 2004, 47, 1879-1881.
26. Lin, Z.; Neamati, N.; Zhao, H.; Kiryu, Y.; Turpin, J. A. et al. Chicoric acid analogues as HIV-1 integrase inhibitors. J. Med. Chem. 1999, 42, 1401-1414.
27. Zhao, H.; Neamati, N.; Sunder, S.; Hong, H.; Wang, S. et al. Hydrazide-containing inhibitors of HIV-1 integrase. J. Med. Chem. 1997, 40, 937-941.
28. Neamati, N.; Mazumder, A.; Zhao, H.; Sunder, S.; Burke, T. R., Jr. et al. Diaryl sulfones, a novel class of human immunodeficiency virus type 1 integrase inhibitors. Antimicrob. Agents Chemother. 1997, 41, 385-393.
29. Mazumder, A.; Neamati, N.; Sunder, S.; Schulz, J.; Pertz, H. et al. Curcumin analogues with altered potencies against HIV-1 integrase as probes for biochemical mechanisms of drug action. J. Med. Chem. 1997, 40, 3057-3063.
30. Neamati, N.; Mazumder, A.; Sunder, S.; Owen, J. M.; Schultz, R. J. et al. 2-Mercaptobenzenesulphonamides as novel inhibitors of human immunodeficiency virus type 1 integrase and replication. Antiviral Chem. Chemother. 1997, 8, 485-495.
31. Neamati, N.; Hong, H.; Mazumder, A.; Wang, S.; Sunder, S. et al. Depsides and depsidones as inhibitors of HIV-1 integrase: discovery of novel inhibitors through 3D database searching. J. Med. Chem. 1997, 40, 942-951.
32. Neamati, N.; Hong, H.; Sunder, S.; Milne, G. W.; Pommier, Y. Potent inhibitors of human immunodeficiency virus type 1 integrase: identification of a novel four-point pharmacophore and tetracyclines as novel inhibitors. Mol. Pharmacol. 1997, 52, 1041-1055.
33. Neamati, N.; Hong, H.; Owen, J. M.; Sunder, S.; Winslow, H. E. et al. Salicylhydrazine-containing inhibitors of HIV-1 integrase: implication for a selective chelation in the integrase active site. J. Med. Chem. 1998, 41, 3202-3209.
34. Zhao, H.; Neamati, N.; Hong, H.; Mazumder, A.; Wang, S. et al. Coumarin-based inhibitors of HIV integrase. J. Med. Chem. 1997, 40, 242-249.
35. Marchand, C.; Zhang, X.; Pais, G. C.; Cowansage, K.; Neamati, N. et al. Structural determinants for HIV-1 integrase inhibition by beta-diketo acids. J. Biol. Chem. 2002, 277, 12596-12603.
36. Neamati, N.; Turpin, J. A.; Winslow, H. E.; Christensen, J. L.; Williamson, K. et al. Thiazolothiazepine inhibitors of HIV-1 integrase. J. Med. Chem. 1999, 42, 3334-3341.
37. Pais, G. C.; Zhang, X.; Marchand, C.; Neamati, N.; Cowansage, K. et al. Structure activity of 3-aryl-1,3-diketo-containing compounds as HIV-1 integrase inhibitors. J. Med. Chem. 2002, 45, 3184-3194.
38. Zhang, X.; Pais, G. C.; Svarovskaia, E. S.; Marchand, C.; Johnson, A. A. et al. Azido-Containing aryl beta-Diketo acid HIV-1 integrase inhibitors. Bioorg. Med. Chem. Lett. 2003, 13, 1215-1219.
39. Singh, S. B.; Jayasuriya, H.; Salituro, G. M.; Zink, D. L.; Shafiee, A. et al. The complestatins as HIV-1 integrase inhibitors. Efficient isolation, structure elucidation, and inhibitory activities of isocomplestatin, chloropeptin I, new complestatins, A and B, and acid-hydrolysis products of chloropeptin I. J. Nat. Prod. 2001, 64, 874-882.
40. Zhang, X.; Neamati, N.; Lee, Y. K.; Orr, A.; Brown, R. D. et al. Arylisothiocyanate-containing esters of caffeic acid designed as affinity ligands for HIV-1 integrase. Bioorg. Med. Chem. 2001, 9, 1649-1657.
41. Ridley, C. P.; Reddy, M. V.; Rocha, G.; Bushman, F. D.; Faulkner, D. J. Total synthesis and evaluation of lamellarin alpha 20-Sulfate analogues. Bioorg. Med. Chem. 2002, 10, 3285-3290.
42. Rowley, D. C.; Hansen, M. S.; Rhodes, D.; Sotriffer, C. A.; Ni, H. et al. Thalassiolins A-C: new marine-derived inhibitors of HIV cDNA integrase. Bioorg. Med. Chem. 2002, 10, 3619-3625.
43. Lee, J. Y.; Park, J. H.; Lee, S. J.; Park, H.; Lee, Y. S. Styrylquinazoline derivatives as HIV-1 integrase inhibitors. Arch. Pharm. (Weinheim) 2002, 335, 277-282.
44. Singh, S. B.; Zink, D. L.; Heimbach, B.; Genilloud, O.; Teran, A. et al. Structure, stereochemistry, and biological activity of integramycin, a novel hexacyclic natural product produced by Actinoplanes sp. that inhibits HIV-1 integrase. Org. Lett. 2002, 4, 1123-1126.
45. Hazuda, D. J.; Felock, P.; Witmer, M.; Wolfe, A.; Stillmock, K. et al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 2000, 287, 646-650.